# Contents

**Introduction and objectives** **XV**

**1 Glucose Metabolism and Diabetes Mellitus** **1**

1.1 Introduction to glucose metabolism . . . . . 2

1.1.1 Endocrine Regulation of Glucose Metabolism . . . . . 2

1.2 Diabetes Mellitus: definition and history . . . . . 6

1.2.1 Brief history of the disease . . . . . 7

1.2.2 Types of Diabetes . . . . . 9

1.3 DM1 and complications of the disease . . . . . 10

1.4 Simulating in DM1 . . . . . 14

1.4.1 Hovorka's group simulator [70, 174] . . . . . 16

1.4.2 UVa Simulator [87, 99, 38, 37] . . . . . 20

1.5 Conclusions . . . . . 25

**2 Glucose Control in Type 1 Diabetes** **27**

2.1 Metabolic control monitoring . . . . . 28

2.2 Insulin administration . . . . . 31

2.2.1 Administration devices . . . . . 32

2.3 Open-loop glucose control in type 1 diabetes: intensive insulin therapy . . . . . 35

2.3.1 Intensive insulin therapy: MDI and CSII . . . . . 36

2.4 Closed-loop glucose control in type 1 diabetes: Artificial Pancreas 40

2.4.1 Main Challenges . . . . . 43

2.4.2 Artificial pancreas nowadays . . . . . 46

2.5 Conclusions . . . . . 54

**3 Open-loop Proposal: Combining basal-bolus insulin infusion for tight postpandial glucose control 55**

3.1 Introduction . . . 56
3.2 Theoretical framework: Interval Analisis and Set Inversion . . . 58
3.3 Set-Inversion-Based prandial insulin delivery . . . 61
3.3.1 Output of the algorithm: best basal-bolus combination . 65
3.4 *In silico* evaluation . . . 69
3.4.1 Patient's model identification . . . 71
3.4.2 Metrics used in the *in silico* evaluation . . . 76
3.4.3 Results of the *in silico* evaluation . . . 77
3.4.4 Discussion of the *in silico* evaluation . . . 81
3.5 Clinical validation . . . 87
3.5.1 Characteristics of the study . . . 88
3.5.2 Metrics used and results of the clinical validation . . . 89
3.5.3 Discussion of the clinical validation . . . 90
3.6 Conclusions . . . 92

**4 Closed loop strategy: A reference conditioning method for the reduction of hypoglycemia 95**

4.1 Introduction . . . 96
4.2 Theoretical framework . . . 99
4.2.1 Invariance Control . . . 99
4.2.2 Finite-time invariance achievement via Sliding Mode Reference Conditioning . . . 101
4.3 Safety auxiliary feedback element (SAFE) in diabetes control . 103
4.3.1 Basics of the algorithm . . . 103
4.3.2 Robustness and fault-tolerance properties . . . 107
4.3.3 SM establishment on safety $IOB$ constraints . . . 109
4.3.4 IOB constraints definition . . . 110
4.4 Simulations and results . . . 112
4.4.1 SAFE algorithm simulations illustrating robustness . . . 112
4.4.2 In-silico evaluation using UVA simulator . . . 115
4.5 Conclusions . . . 121

**5 Extending SAFE to improve its performance against variability** **123**
5.1 Theoretical framework . . . . . 124
5.1.1 Monotonicity analysis . . . . . 125
5.2 Interval version of SAFE . . . . . 129
5.3 Simulations and results . . . . . 130
5.4 Conclusions . . . . . 134

**6 Conclusions** **137**
6.1 Publications . . . . . 139

**References** **143**